GlaxoSmithKline Pharmaceuticals · NSE: GLAXO · BSE: 500660
Q1 FY21 results · Apr–Jun 2020
GlaxoSmithKline Pharmaceuticals reported revenue from operations of ₹648.59 crore (down 17.7% from Q1 FY20) and net profit of ₹110.83 crore (down 2.4% from Q1 FY20) for Q1 FY21 (Apr–Jun 2020), on a consolidated basis.
| Item | Q1 FY21 | Q1 FY20 | YoY | Q4 FY20 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 648.59 | 787.97 | −17.7% | 775.80 | −16.4% |
| Other income | 57.92 | 30.81 | +88.0% | 15.82 | +266.2% |
| Total income | 706.51 | 818.78 | −13.7% | 791.62 | −10.8% |
| Profit before tax | 149.14 | 176.11 | −15.3% | 176.55 | −15.5% |
| Net profit for the period | 110.83 | 113.54 | −2.4% | 138.07 | −19.7% |
| EPS, basic (₹) | 6.54 | 6.70 | −2.4% | 8.15 | −19.8% |
| Net margin (%) | 17.1 | 14.4 | 17.8 |
| Item | Q1 FY21 | Q1 FY20 | YoY | Q4 FY20 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 648.65 | 788.02 | −17.7% | 775.88 | −16.4% |
| Other income | 57.79 | 30.54 | +89.2% | 15.16 | +281.3% |
| Total income | 706.44 | 818.56 | −13.7% | 791.04 | −10.7% |
| Profit before tax | 149.29 | 176.03 | −15.2% | 176.41 | −15.4% |
| Net profit for the period | 110.96 | 113.46 | −2.2% | 137.94 | −19.6% |
| EPS, basic (₹) | 6.55 | 6.70 | −2.2% | 8.14 | −19.6% |
| Net margin (%) | 17.1 | 14.4 | 17.8 |
Consolidated
- Filed with BSE
- 30 Jul 2020, 13:23 IST
- Board meeting
- 29 Jul 2020
- Period
- 01 Apr 2020 to 30 Jun 2020
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 30 Jul 2020, 13:23 IST
- Board meeting
- 29 Jul 2020
- Period
- 01 Apr 2020 to 30 Jun 2020
- Review status
- Unaudited
- Source
- XBRL filing on BSE